The response of patients with bile acid diarrhoea to the farnesoid x receptor agonist obeticholic acid

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 1, 2015, Pages 54-64

  Walters, J R F ^a   Johnston, I M ^a   Nolan, J D ^a   Vassie, C ^a   Pruzanski, M E ^b   Shapiro, D A ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA HYDROXY 4 CHOLESTEN 3 ONE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; BILE ACID; BILIRUBIN; CHOLEST 4 EN 3 ONE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OBETICHOLIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 6-ETHYLCHENODEOXYCHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLEST-4-EN-3-ONE; FARNESOID X-ACTIVATED RECEPTOR; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BILE ACID METABOLISM; CHOLESTEROL BLOOD LEVEL; CHRONIC DIARRHEA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEFECATION URGENCY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IDIOPATHIC CHRONIC DIARRHEA; IDIOPATHIC DISEASE; ILEUM RESECTION; INTESTINAL DYSMOTILITY; MALE; PRIMARY BILE ACID DIARRHEA; PROTEIN BLOOD LEVEL; SECONDARY BILE ACID DIARRHEA; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CLINICAL TRIAL; DIARRHEA; ILEUM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; CHOLESTENONES; DIARRHEA; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ILEUM; MALE; MIDDLE AGED; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84915747794     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12999     Document Type: Article

References (35)

1. Hofmann AF. The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. Gastroenterology 1967; 52: 752-7.
2. Hofmann AF, Poley JR. Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 1972; 62: 918-34.
3. Thaysen EH, Pedersen L. Idiopathic bile acid catharsis. Gut 1976; 17: 965-70.
4. Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol 2010; 4 : 561-7.
5. Vijayvargiya P, Camilleri M, Shin A, Saenger A. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013; 11: 1232-9.
6. Boyd GS, Merrick MV, Monks R, Thomas IL. Se-75-labeled bile acid analogs, new radiopharmaceuticals for investigating the enterohepatic circulation. J Nucl Med 1981; 22: 720-5.
7. Wedlake L, A'Hern R, Thomas K, Walters JRF, Andreyev HJN. Systematic review: the prevalence of idiopathic bile acid malabsorption (I-BAM) as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome (IBS). Aliment Pharmacol Ther 2009; 30: 707-17.
8. Walters JR. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 426-434.
9. Bajor A, Tornblom H, Rudling M, Ung KA, Simren M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2014; Apr 12. doi: 10.1136/gutjnl-2013-305965. [Epub ahead of print]
10. Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, Le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-94.
11. Hofmann AF, Mangelsdorf DJ, Kliewer SA. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009; 7: 1151-4.
12. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-25.
13. Pattni SS, Brydon WG, Dew T, Walters JRF. Fibroblast Growth Factor 19 and 7a-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Trans Gastroenterol 2012; 3: e18.
14. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther 2013; 38: 967-76.
15. Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013; 304: G940-8.
16. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569-72.
17. Pellicciari R, Costantino G, Camaioni E, et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 2004; 47: 4559-69.
18. Lindor KD. New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011; 29: 113-6.
19. Kowdley KV, Jones D, Luketic V, et al. An international study evaluating the farnesoid x receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2011; 54: S13.
20. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the Farnesoid X Receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82.
21. NIDDK. The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial (FLINT) 2014. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/study/NCT01265498 (accessed 01 August 2014).
22. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994; 19: 28-30.
23. Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994; 35: 90-3.
24. Smith MJ, Cherian P, Raju GS, Dawson BF, Mahon S, Bardhan KD. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 2000; 34: 448-51.
25. Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 117-23.
26. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-6.
27. Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580-8.
28. Wong BS, Camilleri M, Carlson P, et al. Increased Bile Acid Biosynthesis Is Associated with Irritable Bowel Syndrome with Diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15.
29. Johnston IM, Pattni SS, Lin J, et al. Meal stimulated FGF19 response and genetic polymorphisms in Primary Bile Acid Diarrhea. Gastroenterology 2012; 142(Suppl. 1): S-268.
30. Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139(1549-58): 1558.
31. Wong BS, Camilleri M, Carlson PJ, et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222-6.
32. Mroz MS, Keating N, Ward JB, et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut 2013; 63: 808-17.
33. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in infl ammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011; 17: 1322-7.
34. Nolan JD, Johnston IM, Walters JR. Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical signi ficance: a new perspective. Expert Rev Gastroenterol Hepatol 2013; 7: 49-56.
35. Albers JJ, Grundy SM, Cleary PA, Small DM, Lachin JM, Schoenfield LJ. National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. Gastroenterology 1982; 82: 638-46.